Navigation Links
Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
Date:3/18/2013

to $25.3 million of funding over seven years, is facilitating Inovio's development of a universal, preventive HIV DNA vaccine, PENNVAX®-GP.

Operating Expenses Research and development expenses for the quarter and year ended December 31, 2012, were $4.4 million and $18.0 million as compared to $4.2 million and $20.0 million for the same periods in 2011. General and administrative expenses for the quarter and year ended December 31, 2012, were $2.9 million and $10.8 million, compared to $3.3 million and $12.0 million for the quarter and year ended December 31, 2011.

Net Loss Attributable to Common Stockholders The $4.4 million increase in net loss attributable to common stockholders for the year ended December 31, 2012, compared with the year ended 2011 resulted primarily from a significant (non-cash) change in fair value of common stock warrants, based on a required quarterly mark to market adjustment to reflect changes in the Company's stock price, the change in fair market value of our investment in VGX International, and a decrease in grant revenue.

Capital Resources During the year ended December 31, 2012, the Company sold 9,344,611 shares of common stock under its ATM common stock sales agreement for net proceeds of $5.3 million.

As of December 31, 2012, cash and cash equivalents plus short-term investments in certificates of deposit, mutual funds, and municipal bonds were $13.8 million compared with $30.3 million as of December 31, 2011.

Subsequent to year end, the Company sold 8,222,966 shares of common stock under its ATM common stock sales agreement for net proceeds of $5.6 million.

On March 7, 2013, we closed an underwritten offering of 27,377,266 shares of our common stock and warrants to purchase an aggregate of up to 13,688,633 shares of common stock. The shares and warrants were sold in units at a price of $0.55 per unit, with each unit consisting of one share of common stock and a w
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 , Glenmark,s ... positive data in a Phase 2a proof of concept ... Glenmark Pharmaceuticals today announced that its ... antagonist, GRC 17536 has shown positive data in a ... concept study conducted on 138 patients in ...
(Date:9/17/2014)... , Sept. 17, 2014  Millions of people suffer ... disc disease. Recently the FDA approved the ... disc, an innovative implant device developed by Spinal Kinetics, which ... in neck and or arm pain. Hospital for Special Surgery ... the only hospital in New York City ...
(Date:9/17/2014)... , Sept. 17, 2014  Members of the ... Interventional Associates announced today that the enterprise ... enhance its image sharing capabilities and provide immediate ... network failures. In addition, the Dicom Systems enterprise ... disparate PACS systems to more effectively deliver the ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3
... 5, 2007 - First-in-human results for,IMC-A12, a monoclonal ... targeted to IGF-1R (insulin-like,growth factor type 1 receptor), ... Society of Clinical Oncology in Chicago.,The IGF-IR is ... cancers,and transmits signals that lead to tumor cell ...
... – This,year’s American Society of Clinical Oncology ... promising new data presented regarding,Merck KGaA’s targeted ... efficacy and,versatility of this agent in both ... (mCRC) and squamous cell,carcinoma of the head ...
Cached Medicine Technology:Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 2Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 3Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 2Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 3Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 4Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 5Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 6Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 7Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 8
(Date:9/17/2014)... September 18, 2014 The global ablation ... of 9.6% from 2014 to 2019. Although mature markets ... hold larger shares in the ablation technologies market in ... the highest CAGR of 12.8% in the next five ... healthcare infrastructure, growing number of hospitals and surgical centers, ...
(Date:9/17/2014)... September 18, 2014 Recently, UWDress.com, an ... and women’s special occasion outfits, has released its 2014 ... addition, the firm has launched a big sale for ... now available at deeply discounted rates, from 15 to ... the company insists on using comfortable to wear materials. ...
(Date:9/17/2014)... A ball gown is the most formal ... full-skirted gown reaching the floor, made of luxurious fabric, ... occasion gown manufacturer and retailer, has delightedly unveiled its ... gowns are offered at discounted rates. , Most versions ... gowns are typically worn with a stole (a formal ...
(Date:9/17/2014)... IntimateRider, an inventor of classy sexual enhancement ... it has entered into a dealership agreement with new ... reason for the deal is the fact that All ... its sales potential, representatives at the mobility products firm ... latest products on the market both nationally and internationally." ...
(Date:9/17/2014)... Dr. Shalev is a Texas native, and grew ... at the University of Texas, and graduated with a Bachelors ... real passion lay in dentistry, and she went on to ... Texas Health Science Center at Houston School of Dentistry. Dr. ... of The Greater Houston Dental Society, and the Texas Dental ...
Breaking Medicine News(10 mins):Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Fecbek.com: Ladies Can Be Elegant Enough to Draw Everyone’s Attention by Wearing Trendy Ball Gowns 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 3
... IVIG worked. Its ability to treat autoimmune diseases seemed ... immunoglobulin (IVIG) is a complex mixture of IgG antibodies ... from thousands of people, and is only FDA-approved to ... it off-label with varied success in patients with lupus, ...
... geographic convenience and the quality of services that can ... to an article// in the latest edition of the ... a developing trend towards urban centralisation of surgical services, ... care standards. ,However, this creates geographical distances ...
... The Public Works and Government Services Canada said that there ... programs this year.// ,The vaccine instead of being ... in the month of November. Dr. Sheela Basrur, Ontario's chief ... by the beginning of the flu season. Public Works buys ...
... a study conducted by Prof Bernard a senior lecturer at ... found that more number// of rural people of heart attacks ... ,Statistics show that heart disease mortality rates in rural areas ... in women than in urban areas. But the solution to ...
... Australians who have type 2 diabetes could also be at ... the latest issue of the Medical Journal of Australia.// ... Renal Impairment cO-existing with NIDDM (non-insulin dependent diabetes mellitus) - ... ever undertaken in Australian general practice. ,NEFRON examined ...
... A study in Britain has found that nearly one-third of ... purpose, due to rupture, or simply slipping off// during sex, ... ,NOP world undertook a survey of nearly 497 people for ... nearly 64% were groping in the dark about the reasons ...
Cached Medicine News:Health News:Single Sugar Enables Antibody to Treat Inflammation 2Health News:Single Sugar Enables Antibody to Treat Inflammation 3Health News:Bolster Rural Surgical Services 2
... androgen secreted into the blood. In males, ... of the testes; in females ca. 50% ... of androstenedione, ca. 25% from the ovary ... The Testosterone ELISA KIT is based on ...
Microalbumin EIA Lipid / Protein Quantification 024-IDC-12...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Medicine Products: